TECH · Bio-Techne Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $316.18M | $295.88M | $289.46M | $297.03M | $316.18M | $289.46M | $272.60M | $303.43M | $276.94M | $271.58M |
| Cost of Revenue | $103.13M | $104.60M | $98.44M | $103.14M | $101.63M | $106.44M | $96.01M | $98.83M | $91.74M | $88.22M |
| Gross Profit | $208.29M | $191.28M | $188.11M | $193.89M | $214.56M | $183.02M | $176.59M | $204.60M | $185.19M | $183.36M |
| R&D | $23.45M | $23.13M | $24.24M | $25.02M | $24.58M | $23.87M | $22.92M | $25.76M | $24.00M | $22.46M |
| SG&A | $109.34M | $113.69M | $116.21M | $121.45M | $151.27M | $119.16M | $115.67M | $111.84M | $105.33M | $93.01M |
| Total Operating Expenses | $132.79M | $136.82M | $140.45M | $146.47M | $175.85M | $143.03M | $138.58M | $137.60M | $129.33M | $115.47M |
| D&A | - | - | $24.34M | - | - | $28.14M | - | - | $28.54M | - |
| Operating Income | $75.50M | $54.46M | $47.66M | $47.42M | $38.71M | $39.99M | $38.00M | $67.00M | $55.86M | $67.89M |
| Interest Expense | $2.40M | $2.17M | $2.93M | $4.33M | $4.00M | $2.18M | $4.33M | $4.00M | $4.89M | $2.36M |
| Income Tax | $20.18M | $12.78M | $9.81M | $7.99M | $15.69M | $6.57M | $5.92M | $12.03M | ($1.44M) | $16.42M |
| Net Income | $51.05M | $38.01M | $38.19M | $34.89M | $22.59M | $33.60M | $27.46M | $49.06M | $50.99M | $50.01M |
| EPS - Basic | $0.33 | $0.24 | $0.25 | $0.22 | $0.14 | $0.21 | $0.17 | $0.31 | $0.32 | $0.32 |
| EPS - Diluted | $0.32 | $0.24 | $0.24 | $0.22 | $0.14 | $0.21 | $0.17 | $0.31 | $0.31 | $0.31 |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $209.82M | $172.88M | $144.96M | $162.19M | $140.67M | $187.54M | $151.79M | $139.91M | $148.66M | $180.57M |
| Accounts Receivable | $214.56M | $184.61M | $183.90M | $206.88M | $237.14M | $223.69M | $241.39M | $227.89M | $204.57M | $218.47M |
| Inventory | $201.18M | $205.45M | $203.19M | $189.45M | $191.08M | $185.04M | $179.73M | $179.50M | $186.08M | $171.64M |
| Accounts Payable | $23.49M | $26.27M | $30.16M | $25.31M | $31.64M | $31.56M | $37.97M | $28.89M | $28.08M | $25.68M |
| Current Assets | $688.05M | $637.43M | $609.51M | $608.30M | $627.24M | $648.57M | $617.42M | $610.65M | $591.48M | $621.48M |
| Total Assets | $2.55B | $2.52B | $2.53B | $2.56B | $2.64B | $2.74B | $2.70B | $2.72B | $2.76B | $2.64B |
| Current Liabilities | $153.28M | $140.43M | $144.54M | $175.85M | $169.20M | $142.13M | $159.38M | $149.82M | $127.75M | $128.51M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $2.09B | $1.92B | $1.97B | $2.08B | $2.02B | $2.14B | $2.07B | $2.01B | $2.00B | $1.97B |
| Retained Earnings | $1.15B | $1.11B | $1.08B | $1.07B | $1.20B | $1.34B | $1.33B | $1.30B | $1.33B | $1.31B |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $27.59M | - | - | $63.89M | - | - | $59.38M | - |
| Investing Cash Flow | - | - | $605.0K | - | - | ($21.68M) | - | - | ($154.11M) | - |
| Financing Cash Flow | - | - | ($44.20M) | - | - | ($11.57M) | - | - | $71.51M | - |
| CapEx | - | - | $5.36M | - | - | $9.17M | - | - | $13.59M | - |
| Free Cash Flow | - | - | $22.22M | - | - | $54.72M | - | - | $45.79M | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 65.9% | 64.6% | 65.0% | 65.3% | 67.9% | 63.2% | 64.8% | 67.4% | 66.9% | 67.5% |
| Operating margin | 23.9% | 18.4% | 16.5% | 16.0% | 12.2% | 13.8% | 13.9% | 22.1% | 20.2% | 25.0% |
| EBITDA margin | - | - | 24.9% | - | - | 23.5% | - | - | 30.5% | - |
| Net margin | 16.1% | 12.8% | 13.2% | 11.7% | 7.1% | 11.6% | 10.1% | 16.2% | 18.4% | 18.4% |
| Free cash flow margin | - | - | 7.7% | - | - | 18.9% | - | - | 16.5% | - |
| FCF / Net income | - | - | 0.58 | - | - | 1.63 | - | - | 0.90 | - |
| R&D / Revenue | 7.4% | 7.8% | 8.4% | 8.4% | 7.8% | 8.2% | 8.4% | 8.5% | 8.7% | 8.3% |
| SG&A / Revenue | 34.6% | 38.4% | 40.1% | 40.9% | 47.8% | 41.2% | 42.4% | 36.9% | 38.0% | 34.2% |
| Effective tax rate | 28.3% | 25.2% | 20.4% | 18.6% | 41.0% | 16.4% | 17.7% | 19.7% | -2.9% | 24.7% |
| Return on assets | 2.0% | 1.5% | 1.5% | 1.4% | 0.9% | 1.2% | 1.0% | 1.8% | 1.9% | 1.9% |
| Return on equity | 2.4% | 2.0% | 1.9% | 1.7% | 1.1% | 1.6% | 1.3% | 2.4% | 2.6% | 2.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.49 | 4.54 | 4.22 | 3.46 | 3.71 | 4.56 | 3.87 | 4.08 | 4.63 | 4.84 |
| Quick ratio | 3.18 | 3.08 | 2.81 | 2.38 | 2.58 | 3.26 | 2.75 | 2.88 | 3.17 | 3.50 |
| Cash ratio | 1.37 | 1.23 | 1.00 | 0.92 | 0.83 | 1.32 | 0.95 | 0.93 | 1.16 | 1.41 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 31.4x | 25.1x | 16.2x | 11.0x | 9.7x | 18.4x | 8.8x | 16.7x | 11.4x | 28.8x |
| Equity multiplier | 1.22 | 1.31 | 1.29 | 1.23 | 1.31 | 1.28 | 1.31 | 1.35 | 1.38 | 1.34 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | 0.12 | 0.11 | 0.12 | 0.12 | 0.11 | 0.10 | 0.11 | 0.10 | 0.10 |
| Inventory turnover | 0.51 | 0.51 | 0.48 | 0.54 | 0.53 | 0.58 | 0.53 | 0.55 | 0.49 | 0.51 |
| Days sales outstanding | 248d | 228d | 232d | 254d | 274d | 282d | 323d | 274d | 270d | 294d |
| Days inventory outstanding | 712d | 717d | 753d | 670d | 686d | 635d | 683d | 663d | 740d | 710d |
| Days payable outstanding | 83d | 92d | 112d | 90d | 114d | 108d | 144d | 107d | 112d | 106d |
| Cash conversion cycle | 877d | 853d | 873d | 835d | 846d | 808d | 862d | 830d | 898d | 897d |
| Valuation | ||||||||||
| P / E | 163.3x | 245.0x | 231.8x | 233.9x | 418.8x | 380.6x | 421.5x | 227.1x | 219.6x | 263.3x |
| P / B | 3.9x | 4.8x | 4.4x | 4.0x | 4.6x | 6.0x | 5.5x | 5.6x | 5.5x | 6.7x |
| P / S | 26.0x | 31.2x | 30.1x | 27.8x | 29.5x | 44.5x | 42.1x | 37.2x | 39.8x | 48.6x |
| EV / EBITDA | - | - | 118.8x | - | - | 186.3x | - | - | 128.8x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 0.0% | -0.4% | 0.0% | 9.0% | 4.2% | 4.5% | 0.4% | 3.2% | 2.7% | 0.9% |
| Revenue CAGR (3y) | 2.4% | 2.9% | 2.4% | 3.3% | 2.9% | 3.9% | 6.7% | 7.6% | 10.7% | 13.7% |
| Revenue CAGR (5y) | 5.4% | 5.7% | 7.2% | 9.9% | 10.2% | 9.6% | 9.3% | 10.4% | 11.2% | 12.0% |
| Gross profit growth (YoY) | -2.9% | -1.3% | 2.8% | 9.8% | 4.9% | -1.2% | -3.7% | 1.2% | 3.1% | -0.2% |
| Operating income growth (YoY) | 95.0% | 14.9% | 19.2% | 24.8% | -42.2% | -28.4% | -44.0% | -16.5% | -0.8% | 8.9% |
| Net income growth (YoY) | 126.0% | 8.9% | 13.6% | 27.0% | -54.0% | -34.1% | -45.1% | -30.1% | -43.1% | -37.6% |
| EPS growth (YoY) | 128.6% | 9.1% | 14.3% | 29.4% | -54.8% | -32.3% | -45.2% | -27.9% | -86.0% | -84.0% |
| EPS CAGR (3y) | -9.4% | -8.2% | -52.3% | -51.6% | -54.4% | -50.1% | -47.1% | -34.8% | -28.0% | -53.2% |
| EPS CAGR (5y) | -22.2% | -26.9% | -22.0% | -40.8% | -31.4% | -10.7% | -17.7% | -23.1% | -7.2% | -24.8% |
| FCF growth (YoY) | - | - | -59.4% | - | - | 19.5% | - | - | -1.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | 12.8% | - | - | 3.0% | - |
| Book value growth (YoY) | 3.3% | -7.7% | -8.1% | 0.5% | 0.2% | 7.1% | 5.2% | 6.6% | 14.1% | 15.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Business segments
$1.22B totalProtein Sciences$870.25M · 71.5%
Diagnostics And Spatial Biology$346.26M · 28.5%
Product / service
$2.42B totalProduct And Services$1.20B · 49.5%
Consumables$972.29M · 40.3%
Instruments$112.09M · 4.6%
Service$111.57M · 4.6%
Royalty$23.69M · 1.0%
Geographic
$1.22B totalUS$683.23M · 56.0%
EMEAExcluding UK$266.31M · 21.8%
CN$100.46M · 8.2%
APACExcluding Greater China$77.26M · 6.3%
GB$54.83M · 4.5%
Rest Of World$37.55M · 3.1%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing BIO-TECHNE Corp against the 5 most active filers in the same SIC group.
Dividends
$0.32/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 18, 2026 | $0.0800 |
| Feb 13, 2026 | $0.0800 |
| Nov 17, 2025 | $0.0800 |
| Aug 18, 2025 | $0.0800 |
| May 19, 2025 | $0.0800 |
| Feb 14, 2025 | $0.0800 |
| Nov 8, 2024 | $0.0800 |
| Aug 19, 2024 | $0.0800 |
| May 10, 2024 | $0.0800 |
| Feb 9, 2024 | $0.0800 |
| Nov 9, 2023 | $0.0800 |
| Aug 17, 2023 | $0.0800 |
| May 12, 2023 | $0.0800 |
| Feb 10, 2023 | $0.0800 |
| Nov 10, 2022 | $0.0800 |
| Aug 12, 2022 | $0.0800 |
| May 13, 2022 | $0.0800 |
| Feb 10, 2022 | $0.0800 |
| Nov 10, 2021 | $0.0800 |
| Aug 13, 2021 | $0.0800 |
| May 14, 2021 | $0.0800 |
| Feb 11, 2021 | $0.0800 |
| Nov 13, 2020 | $0.0800 |
| Aug 17, 2020 | $0.0800 |